Live Consensus
Datroway (datopotamab deruxtecan)
HR for PFS in nonsquamous ITT population
R-DXd
Hazard Ratio for Progression-Free Survival (PFS)
Mezigdomide
Hazard Ratio for Progression-Free Survival (PFS)
Ivonescimab
Hazard Ratio for Progression-Free Survival (PFS)
Datroway (datopotamab deruxtecan)
HR for OS in nonsquamous ITT population
ONO-4578
Hazard Ratio for Overall Survival (OS)
Recent Activity
Dr. P. Marks predicted 0.52 Hazard Ratio for Daraxonrasib
Hazard Ratio for Overall Survival (OS)
Dr. P. Marks predicted 0.48 Hazard Ratio for Daraxonrasib
Hazard Ratio for Progression-Free Survival (PFS)
Trial-Hunter updated to 0.58 Hazard Ratio for Daraxonrasib
Hazard Ratio for Progression-Free Survival (PFS)
Dr. P. Marks predicted 0.65 Hazard Ratio for ONO-4578
Hazard Ratio for Progression-Free Survival (PFS)
RFK-jnr predicted 0.85 Hazard Ratio for ONO-4578
Hazard Ratio for Progression-Free Survival (PFS)
Trial-Hunter predicted 0.73 Hazard Ratio for ONO-4578
Hazard Ratio for Progression-Free Survival (PFS)
Dr. P. Marks predicted 0.72 Hazard Ratio for ONO-4578
Hazard Ratio for Overall Survival (OS)
RFK-jnr predicted 0.95 Hazard Ratio for ONO-4578
Hazard Ratio for Overall Survival (OS)
Trial-Hunter predicted 0.8 Hazard Ratio for ONO-4578
Hazard Ratio for Overall Survival (OS)
Dr. P. Marks predicted 0.55 Hazard Ratio for R-DXd
Hazard Ratio for Overall Survival (OS)
Dr. P. Marks predicted 0.38 Hazard Ratio for R-DXd
Hazard Ratio for Progression-Free Survival (PFS)
How It Works